Iridium Corporation logo

Iridium Corporation (IRMD)

Market Closed
1 Sep, 20:00
NASDAQ (NMS) NASDAQ (NMS)
$
86. 38
0
0%
$
1.11B Market Cap
34.27 P/E Ratio
0.8% Div Yield
68,336 Volume
1.49 Eps
$ 86.38
Previous Close
Add Transaction
Day Range
86.08 87.78
Year Range
67.84 107.9
Want to track IRMD and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
IRadimed Corporation: Steady, Low-Risk Grower In The Devices Space

IRadimed Corporation: Steady, Low-Risk Grower In The Devices Space

IRadimed Corporation offers steady revenue growth with 14 consecutive quarters of record revenue and a small dividend, despite recent stock price decline. IRMD's unique MRI-compatible IV infusion pump and patient monitoring system face limited competition, ensuring a strong market position. Financials show robust performance with a 21% increase in US sales, but international sales dipped possibly due to cheaper alternatives in Asian markets.

Seekingalpha | 1 year ago
IRADIMED CORPORATION (IRMD) Q4 2024 Earnings Call Transcript

IRADIMED CORPORATION (IRMD) Q4 2024 Earnings Call Transcript

IRADIMED CORPORATION (NASDAQ:IRMD ) Q4 2024 Earnings Conference Call February 13, 2025 11:00 AM ET Company Participants Roger Susi - Founder, President and CEO John Glenn - Chief Financial Officer Conference Call Participants Jason Wittes - ROTH Capital Partners Nelson Cox - Lake Street Capital Markets Operator Welcome to the IRADIMED CORPORATION Fourth Quarter of 2024 Financial Results Conference Call. Currently, all participants are in a listen-only mode.

Seekingalpha | 1 year ago
IRadimed (IRMD) Lags Q4 Earnings Estimates

IRadimed (IRMD) Lags Q4 Earnings Estimates

IRadimed (IRMD) came out with quarterly earnings of $0.44 per share, missing the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.39 per share a year ago.

Zacks | 1 year ago
iRadimed (IRMD) Is a Great Choice for 'Trend' Investors, Here's Why

iRadimed (IRMD) Is a Great Choice for 'Trend' Investors, Here's Why

If you are looking for stocks that are well positioned to maintain their recent uptrend, iRadimed (IRMD) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Zacks | 1 year ago
Here's Why Momentum in iRadimed (IRMD) Should Keep going

Here's Why Momentum in iRadimed (IRMD) Should Keep going

iRadimed (IRMD) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Zacks | 1 year ago
iRadimed (IRMD) is on the Move, Here's Why the Trend Could be Sustainable

iRadimed (IRMD) is on the Move, Here's Why the Trend Could be Sustainable

iRadimed (IRMD) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Zacks | 1 year ago
IRADIMED CORPORATION (IRMD) Q3 2024 Earnings Call Transcript

IRADIMED CORPORATION (IRMD) Q3 2024 Earnings Call Transcript

IRADIMED CORPORATION. (NASDAQ:IRMD ) Q3 2024 Earnings Conference Call October 31, 2024 11:00 AM ET Company Participants Roger Susi - President and Chief Executive Officer Jack Glenn - CFO Conference Call Participants Frank Takkinen - Lake Street Capital Markets Jason Wittes - ROTH Capital Partners Operator Welcome to the IRadimed Corporation Third Quarter of 2024 Financial Results Conference Call.

Seekingalpha | 1 year ago
IRadimed (IRMD) Beats Q3 Earnings and Revenue Estimates

IRadimed (IRMD) Beats Q3 Earnings and Revenue Estimates

IRadimed (IRMD) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Estimate of $0.39 per share. This compares to earnings of $0.43 per share a year ago.

Zacks | 1 year ago
IRADIMED CORPORATION (IRMD) Q2 2024 Earnings Call Transcript

IRADIMED CORPORATION (IRMD) Q2 2024 Earnings Call Transcript

IRADIMED CORPORATION (NASDAQ:IRMD ) Q2 2024 Results Conference Call August 1, 2024 12:00 PM ET Company Participants Roger Susi - President and Chief Executive Officer Matt Garner - Controller Conference Call Participants Frank Takkinen - Lake Street Capital Jason Wittes - ROTH Capital Partners Operator Welcome to the IRadimed Corporation Second Quarter of 2024 Financial Results Conference Call. [Operator Instructions] As a reminder, this call is being recorded today, August 1, 2024, and contains time-sensitive accurate information only today.

Seekingalpha | 2 years ago
IRadimed (IRMD) Surpasses Q2 Earnings and Revenue Estimates

IRadimed (IRMD) Surpasses Q2 Earnings and Revenue Estimates

IRadimed (IRMD) came out with quarterly earnings of $0.42 per share, beating the Zacks Consensus Estimate of $0.36 per share. This compares to earnings of $0.36 per share a year ago.

Zacks | 2 years ago